Recombinant Human Monocarboxylate Transporter 5 (SLC16A4) Protein (His)

Name: Recombinant Human Monocarboxylate Transporter 5 (SLC16A4) Protein (His)
Brand: Beta LifeScience
SKU: BLC-01785P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Monocarboxylate Transporter 5 (SLC16A4) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	O15374
Target Symbol	SLC16A4
Synonyms	Monocarboxylate transporter 4 Solute carrier family 16 member 4
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His
Target Protein Sequence	RPIHIKSENNSGIKDKGSSLSAHGPEAHATETHCHETEESTIKDSTTQKAGLPSKNLTVSQNQSEEFYNGPNRNRLLLKSDEESDKVISWSCKQLFDISLFRNP
Expression Range	196–299aa
Protein Length	Partial
Mol. Weight	17.7 kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate.
Subcellular Location	Cell membrane; Multi-pass membrane protein.
Protein Families	Major facilitator superfamily, Monocarboxylate porter (TC 2.A.1.13) family
Database References	HGNC: 10925 OMIM: 603878 KEGG: hsa:9122 UniGene: PMID: 30226548 High MCT-4 expression is associated with clear cell renal cell carcinoma. PMID: 29657088 Nrf2 overexpression upregulated MCT1, but decreased MCT4 expression in premalignant and malignant colonic epithelial cells. PMID: 28846107 These results demonstrate that Monocarboxylate transporters tend to play a role in the aggressive breast cancer subtypes through the dynamic interaction between breast cancer cells and adipocytes. PMID: 29775610 Elevated MCT4 protein expression in clinical prostate cancer specimens was associated with increases in Gleason grade, prolonged treatment of patients with neoadjuvant hormone therapy, castration resistant prostate cancer, and early disease relapse. PMID: 26755530 our finding that the expression of MCT1 and MCT4 is reduced in mutant IDH1 gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 tumors and has important implications for our understanding of these tumors and their treatment PMID: 27144334 Results suggest that MCT4 plays a central role in tumor metabolism in gastric cancer (GC) with peritoneal carcinomatosis and targeting MCT4 in combination with chemotherapy could be a novel strategy in the treatment of GC. PMID: 27224918 TOMM20, MCT1, and MCT4 expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. High MCT4 expression was found in tumor associated macrophages, but absent in HRS cells in all but one case. Tumor-infiltrating lymphocytes had absent MCT4 expression. Reactive lymph nodes in contrast to cHL tumors had low TOMM20, MCT1, and MCT4 expression in lymphocytes and macrophages. PMID: 29248133 Stromal cells in diffuse large B-cell lymphoma samples strongly expressed MCT4, displaying a glycolytic phenotype, a feature not seen in stromal elements of non-neoplastic lymphatic tissue. PMID: 29248132 The structures and functions of hMCT1 and hMCT4 transporters. PMID: 28559188 MCT1 inhibitor AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux. PMID: 28923861 The reversible H(+)/lactate(-) symporter MCT4 cotransports lactate and proton, leading to the net extrusion of lactic acid in glycolytic tumors. A model of its role in pH control in tumor cells is described. Review. PMID: 26944480 Increased miR-210 and concomitant decreased ISCU RNA levels were found in ~40% of tumors and this was significantly associated with HIF-1alpha and CAIX, but not MCT1 or MCT4, over-expression. PMID: 28099149 High expression of MCT4 is associated with inflammation in arsenite-induced liver carcinogenesis. PMID: 28419250 The loss expression of Cav-1 on CAFs and the up-regulation of MCT4 may be the possible mechanisms of CAFs in tumorigenesis. PMID: 28625953 MCT1 and MCT4 expression levels were associated with worse prognosis and shorter overall survival. PMID: 27105345 We demonstrated that the expression levels of glycolysis-related proteins glucose transporter 1, hexokinase II, carbonic anhydrase IX, and monocarbonylate transporter 4 differ between thyroid cancer subtypes and are correlated with poorer prognosis PMID: 28347233 Data suggest that inhibition of mnocarboxylate transporters MCT1 and MCT4 may have clinical relevance in pancreatic ductal adenocarcinoma (PDAC). PMID: 26765963 MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 via disruption of pyruvate rather than lactate export. PMID: 26876179 MCT1 expression was not clearly associated with overall or disease-free survival. MCT4 and CD147 expression correlate with worse prognosis across many cancer types. These results warrant further investigation of these associations PMID: 26779534 Prognostic significance of CD147 protein expression could not surpass that of MCT4, especially of SLC16A3 DNA methylation, corroborating the role of MCT4 as prognostic biomarker for ccRCC. PMID: 26384346 MCT4 expression is regulated by the PI3K-Akt signalling pathway and highly expressed in HER2-positive breast cancers where it regulates tumor cell metabolism and survival. PMID: 25965974 Knockdown of MCT4 blocks lactate efflux to result in lactic acid accumulation and pH dropping, which is involved in triggering apoptosis in HUVECs. PMID: 26363456 we showed that genetic disruption of Mct4 and/or Ampk dramatically reduced tumourigenicity in a xenograft mouse model suggesting a crucial role for these two actors in establishment of tumours in a nutrient-deprived environment PMID: 26059436 synovial fibroblasts from patients with rheumatoid arthritis exhibited up-regulated transcription of MCT4 mRNA compared with osteoarthritis patients. Knockdown of MCT4 induced intrinsic apoptosis of fibroblasts, thereby inhibiting their proliferation. PMID: 26213210 The first IF method has been developed and optimised for detection of MCT 1 and MCT4 in cancer patient circulating tumour cells . PMID: 25957999 Findings demonstrate that the histidine residue His382 in the extracellular loop of the transporter is essential for pH regulation of MCT4-mediated substrate transport activity. PMID: 25919709 Decreased astroglial monocarboxylate transporter 4 expression in temporal lobe epilepsy PMID: 24464262 MCT4 expression can predict survival and trans-arterial chemoembolization treatment response for hepatocellular carcinoma patients. MCT4 plays a role in cell proliferation and migration/invasion. PMID: 25446815 we sought to evaluate the associations of nine functional SNPs in genes encoding MCT1, MCT2, and MCT4 with the prognosis in a cohort of 500 Chinese NSCLC patients. PMID: 25578492 High monocarboxylate transporter 4 protein expression in stromal cells is associated with invasiveness in gastric cancer. PMID: 25374230 These results indicate there are no additional benefits of IHT when compared to similar normoxic training. Hence, the addition of the hypoxic stimulus on anaerobic performance or MCT expression after a three-week training period is ineffective. PMID: 24797797 MCT4 upregulation correlated with the aggressive mesenchymal subset of glioblastoma (GBM), and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. PMID: 24077291 MCT4 is up-regulated in inflammation-activated macrophages and required for innate immune response. PMID: 25406319 Aberrant expression of MCT4 in carcinoma cells serves as a novel, independent prognostic factor for HCC, indicating a poorer patient outcome. PMID: 24433439 MCT4 demonstrated the strongest deleterious impact on survival in triple negative breast cancer patients.MCT4 should serve as a new prognostic factor in node-negative breast cancers. PMID: 25058459 The critical role of MCT4 in cell proliferation. PMID: 24498219 Upregulation of MCT4 expression via SLC16A3 promoter DNA methylation is associated with clear cell renal cell carcinoma. PMID: 23881922 Results suggest that Arginine-278 in transmembrane-spanning domains TMD8 is a critical residue involved in L-lactate recognition by monocarboxylate transporter 4 (hMCT4). PMID: 23935841 Coexpression of CAIV with MCT1 and MCT4 resulted in a significant increase in MCT transport activity. PMID: 24338019 Alterations in Cav-1 and MCT4 expression may mark a critical point in the progression from in situ to invasive breast cancer. PMID: 23907124 MCT1 and MCT4 biomarkers were employed to determine the metabolic state of proliferative cancer cells. PMID: 23574725 High MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. PMID: 23780984 Overexpression of MCT4 is associated with gliomas. PMID: 23258846 Report SNPs in MCT4 (SLC16A3) gene in the Chinese and Indian populations of Singapore. PMID: 22240841 Combined application of GLUT-1, MCT-1, and MCT-4 immunohistochemistry might be useful in differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. PMID: 23187830 High GLUT1 plus high MCT4 expression indicated an aggressive tumor behavior in adenocarcinomas. PMID: 22153830 Data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in renal cell carcinoma. PMID: 22362593 Data show that a significant increase of MCT2 and MCT4 expression in the cytoplasm of tumour cells and a significant decrease in both MCT1 and CD147 expression in prostate tumour cells was observed when compared to normal tissue. PMID: 21787388 both MCT1 and CD147, but not MCT4, were associated with GLUT1 and CAIX expression in a large series of invasive breast carcinoma samples PMID: 21870331

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.